<DOC>
	<DOC>NCT01259648</DOC>
	<brief_summary>The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.</brief_summary>
	<brief_title>Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects</brief_title>
	<detailed_description />
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Patients requiring rapid sequence intubation for whatever reason. This includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux Patient able to give informed consent, and sign the consent. Contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction Morbid obesity (Body Mass Index &gt; 40) Emergency situation with unstable hemodynamics, and stabilization is impossible before induction Inclusion in another research project within the past 3 months The patient is not insured or beneficiary of a health insurance plan (for the French centers) Patient under guardianship of any kind Patient unable to give informed consent Refusal to sign the consent form</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>remifentanil</keyword>
	<keyword>anesthesia induction</keyword>
	<keyword>reactional tachycardia</keyword>
</DOC>